Who Generates Higher Gross Profit? Vertex Pharmaceuticals Incorporated or Vericel Corporation

Vertex Pharmaceuticals leads in gross profit growth over Vericel.

__timestampVericel CorporationVertex Pharmaceuticals Incorporated
Wednesday, January 1, 201411503000519428000
Thursday, January 1, 201524698000906794000
Friday, January 1, 2016260760001491717000
Sunday, January 1, 2017335700002213533000
Monday, January 1, 2018586970002638058000
Tuesday, January 1, 2019802790003615063000
Wednesday, January 1, 2020842280005469383000
Friday, January 1, 20211060250006670200000
Saturday, January 1, 20221097880007850400000
Sunday, January 1, 20231355760008607000000
Monday, January 1, 20249489600000
Loading chart...

In pursuit of knowledge

Vertex Pharmaceuticals vs. Vericel Corporation: A Gross Profit Showdown

In the competitive landscape of biotechnology, Vertex Pharmaceuticals Incorporated and Vericel Corporation have been making significant strides. Over the past decade, Vertex Pharmaceuticals has consistently outperformed Vericel Corporation in terms of gross profit. From 2014 to 2023, Vertex's gross profit surged by an impressive 1,557%, reaching approximately $8.6 billion in 2023. In contrast, Vericel's gross profit grew by 1,079% over the same period, peaking at around $135 million.

This stark difference highlights Vertex's dominant position in the market, driven by its innovative treatments and strategic investments. Meanwhile, Vericel, though smaller in scale, has shown remarkable growth, reflecting its potential in niche markets. As the biotech industry continues to evolve, these companies exemplify the diverse paths to success, with Vertex leading the charge in profitability.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025